JP6325453B2 - ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 - Google Patents

ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 Download PDF

Info

Publication number
JP6325453B2
JP6325453B2 JP2014548965A JP2014548965A JP6325453B2 JP 6325453 B2 JP6325453 B2 JP 6325453B2 JP 2014548965 A JP2014548965 A JP 2014548965A JP 2014548965 A JP2014548965 A JP 2014548965A JP 6325453 B2 JP6325453 B2 JP 6325453B2
Authority
JP
Japan
Prior art keywords
loh
cancer
cancer cells
pair
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506678A (ja
JP2015506678A5 (cg-RX-API-DMAC7.html
Inventor
ビクター アブケビック
ビクター アブケビック
アレクサンダー グティン
アレクサンダー グティン
キルスティン ティムズ
キルスティン ティムズ
ジェリー ランチベリー
ジェリー ランチベリー
Original Assignee
ミリアド・ジェネティックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6325453(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ミリアド・ジェネティックス・インコーポレイテッド filed Critical ミリアド・ジェネティックス・インコーポレイテッド
Publication of JP2015506678A publication Critical patent/JP2015506678A/ja
Publication of JP2015506678A5 publication Critical patent/JP2015506678A5/ja
Application granted granted Critical
Publication of JP6325453B2 publication Critical patent/JP6325453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014548965A 2011-12-21 2012-12-21 ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 Active JP6325453B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161578713P 2011-12-21 2011-12-21
US61/578,713 2011-12-21
US201261654402P 2012-06-01 2012-06-01
US61/654,402 2012-06-01
PCT/US2012/071380 WO2013096843A1 (en) 2011-12-21 2012-12-21 Methods and materials for assessing loss of heterozygosity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076503A Division JP6700333B2 (ja) 2011-12-21 2018-04-12 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料

Publications (3)

Publication Number Publication Date
JP2015506678A JP2015506678A (ja) 2015-03-05
JP2015506678A5 JP2015506678A5 (cg-RX-API-DMAC7.html) 2016-02-04
JP6325453B2 true JP6325453B2 (ja) 2018-05-16

Family

ID=48669561

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014548965A Active JP6325453B2 (ja) 2011-12-21 2012-12-21 ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2018076503A Active JP6700333B2 (ja) 2011-12-21 2018-04-12 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2020079997A Active JP7128853B2 (ja) 2011-12-21 2020-04-30 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2022130844A Active JP7595619B2 (ja) 2011-12-21 2022-08-19 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2024205398A Pending JP2025032160A (ja) 2011-12-21 2024-11-26 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018076503A Active JP6700333B2 (ja) 2011-12-21 2018-04-12 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2020079997A Active JP7128853B2 (ja) 2011-12-21 2020-04-30 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2022130844A Active JP7595619B2 (ja) 2011-12-21 2022-08-19 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
JP2024205398A Pending JP2025032160A (ja) 2011-12-21 2024-11-26 ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料

Country Status (11)

Country Link
US (5) US9388472B2 (cg-RX-API-DMAC7.html)
EP (3) EP4497824A3 (cg-RX-API-DMAC7.html)
JP (5) JP6325453B2 (cg-RX-API-DMAC7.html)
CN (2) CN104160037B (cg-RX-API-DMAC7.html)
AU (4) AU2012358244A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014015152A2 (cg-RX-API-DMAC7.html)
CA (1) CA2860312C (cg-RX-API-DMAC7.html)
DK (1) DK2794907T4 (cg-RX-API-DMAC7.html)
ES (1) ES2759533T5 (cg-RX-API-DMAC7.html)
FI (1) FI2794907T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013096843A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
WO2013096843A1 (en) 2011-12-21 2013-06-27 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
CA2864481C (en) 2012-02-23 2020-07-14 The Children's Hospital Corporation Methods for predicting anti-cancer response
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US11149316B2 (en) 2013-12-09 2021-10-19 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
US20180163271A1 (en) * 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
ES2800673T3 (es) * 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
US20160160294A1 (en) * 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
WO2016185406A1 (en) 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function
WO2017191076A1 (en) * 2016-05-01 2017-11-09 Genome Research Limited Method of characterising a dna sample
GB201607629D0 (en) * 2016-05-01 2016-06-15 Genome Res Ltd Mutational signatures in cancer
CN109219852A (zh) * 2016-05-01 2019-01-15 基因组研究有限公司 表征dna样品的方法
GB2555765A (en) 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
CN107287285A (zh) * 2017-03-28 2017-10-24 上海至本生物科技有限公司 一种预测同源重组缺失机制及患者对癌症治疗响应的方法
EP3658687B1 (en) 2017-07-25 2025-02-26 Sophia Genetics S.A. Methods for detecting biallelic loss of function in next-generation sequencing genomic data
CN112805563B (zh) * 2018-05-18 2025-06-13 约翰·霍普金斯大学 用于评估和/或治疗癌症的无细胞dna
IT201900013335A1 (it) * 2019-07-30 2021-01-30 Menarini Silicon Biosystems Spa Metodo per analizzare la perdita di eterozigosi (loh) a seguito di amplificazione totale del genoma basata su un sito di restrizione deterministico (drs-wga)
JP2023500460A (ja) * 2019-10-29 2023-01-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 処置に対する分子応答に基づく処置の方法
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
CN112410423B (zh) * 2020-11-03 2021-08-13 南京世和基因生物技术股份有限公司 同源重组缺失的标志物、检测方法以及检测系统
CN112226495B (zh) * 2020-12-18 2021-03-16 北京迈基诺基因科技股份有限公司 一种dna同源重组异常的检测方法及其应用
WO2022150063A1 (en) * 2021-01-10 2022-07-14 Act Genomics (Ip) Co., Ltd. Homologous recombination deficiency determining method and kit thereof
US20240026462A1 (en) * 2021-01-10 2024-01-25 Ying Ja CHEN Homologous recombination deficiency determining method and kit thereof
CN113466417B (zh) * 2021-05-13 2023-03-21 柳州东风容泰化工股份有限公司 一种氟尿嘧啶的制备纯度评估方法及系统
US12188961B2 (en) 2022-07-29 2025-01-07 International Business Machines Corporation Method for accurate pad contact testing
WO2024083971A1 (en) 2022-10-19 2024-04-25 Vib Vzw Method of determining loss of heterozygosity status of a tumor
WO2025078387A1 (en) 2023-10-10 2025-04-17 Vib Vzw Method of detecting loss of heterozygosity status of a tumor
WO2025078404A1 (en) 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair
WO2025173014A1 (en) 2024-02-16 2025-08-21 Onecell Diagnostics India Private Limited A method for selecting ovarian cancer patients for parp inhibitor treatment

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3630497A1 (de) 1986-09-08 1988-03-10 Behringwerke Ag Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
HU199492B (en) 1987-05-08 1990-02-28 Sankyo Co Process for producing antitumour platinum complexes and pharmaceutical compositions comprising same
US4996337A (en) 1987-06-23 1991-02-26 American Cyanamid Company Synthesis of cisplatin analogs
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
ZA928771B (en) 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
CA2168096A1 (en) * 1993-07-26 1995-02-02 David E. Housman Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
US6384210B1 (en) 1997-03-20 2002-05-07 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
GB9808145D0 (en) 1998-04-17 1998-06-17 Zeneca Ltd Assay
US20030049613A1 (en) 1998-08-17 2003-03-13 Manuel Perucho Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
JP2002534098A (ja) 1999-01-06 2002-10-15 コーネル リサーチ ファンデーション インク． ゲノムシークエンシングにおける単一ヌクレオチドの多型の加速度的な同定およびクローンの整列化
US6261775B1 (en) 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
JP4287652B2 (ja) 2000-10-24 2009-07-01 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ ゲノムｄｎａの直接多重処理による性状分析
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
EP1339402B1 (en) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
CA2477611A1 (en) 2002-03-01 2003-09-12 Ravgen, Inc. Rapid analysis of variations in a genome
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
WO2004072269A2 (en) 2003-02-12 2004-08-26 Mayo Foundation For Medical Education And Research Bex4 nucleic acids, polypeptides, and method of using
US20040170983A1 (en) * 2003-02-27 2004-09-02 Danenberg Kathleen D. Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus
US20050112604A1 (en) 2003-03-14 2005-05-26 Akihide Fujimoto Loss of heterozygosity of the DNA markers in the 12q22-23 region
US7754684B2 (en) 2003-06-11 2010-07-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
EP1638509B1 (en) 2003-07-02 2015-12-30 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
DK1660095T3 (da) 2003-07-25 2010-05-25 Cancer Rec Tech Ltd Tricykliske PARP-inhibitorer
AU2004264421B2 (en) 2003-08-13 2011-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20080108057A1 (en) 2004-06-22 2008-05-08 Griffith Jeffrey K Allelic imbalance in the diagnosis and prognosis of cancer
CA2584989A1 (en) 2004-10-22 2006-05-04 Sydney David Finkelstein Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation
US20070070349A1 (en) 2005-09-23 2007-03-29 Helicos Biosciences Corporation Optical train and method for TIRF single molecule detection and analysis
EP1856292B1 (en) 2005-03-09 2013-10-30 Abbott Laboratories Diagnostic methods for identifying candidate patients for the treatment with trastuzumab.
US20060234264A1 (en) 2005-03-14 2006-10-19 Affymetrix, Inc. Multiplex polynucleotide synthesis
EP1877576B1 (en) 2005-04-12 2013-01-23 454 Life Sciences Corporation Methods for determining sequence variants using ultra-deep sequencing
CA2605669A1 (en) 2005-04-21 2006-11-02 Ronald D. Alvarez Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes
WO2006128195A2 (en) 2005-05-27 2006-11-30 Dana-Farber Cancer Institute Methods of diagnosing and treating cancer by detection of chromosomal abnormalities
EP1896491B1 (en) 2005-06-30 2010-11-17 Bionumerik Pharmaceuticals, Inc. Monoazole ligand platinum analogs
EP1926835B1 (en) 2005-09-21 2014-12-31 BioArray Solutions Ltd. Message abundance and allele copy number determination using ivt with single-stranded primer-promoter-selector constructs
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20090081237A1 (en) 2007-03-12 2009-03-26 Dana-Farber Cancer Institute Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents
CA2698545C (en) 2007-09-07 2014-07-08 Fluidigm Corporation Copy number variation determination, methods and systems
PL2209375T3 (pl) * 2007-10-03 2014-12-31 Eisai Inc Związki, kompozycje i metody stosowania inhibitorów PARP
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2224804A4 (en) 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
US20090246789A1 (en) 2008-03-25 2009-10-01 University Of South Carolina Gene Mutation Profiling of CSMD1
US20100086922A1 (en) † 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
JP5570516B2 (ja) 2008-10-31 2014-08-13 アッヴィ・インコーポレイテッド 遺伝子コピー数の変化のパターンに基づいた結腸直腸癌のゲノム分類
US8206910B2 (en) * 2008-12-08 2012-06-26 The Cleveland Clinic Foundation Targets for use in diagnosis, prognosis and therapy of breast cancer
KR100925337B1 (ko) 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
WO2011048495A1 (en) 2009-10-19 2011-04-28 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
EP2539468A4 (en) 2010-02-24 2013-08-28 Myriad Genetics Inc DIAGNOSTIC PROCEDURE INCLUDING LOSS OF HETEROZYGOTY
EP3327148B1 (en) * 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
WO2012019000A2 (en) 2010-08-04 2012-02-09 On-Q-ity Biomarkers for the identification monitoring and treatment of ovarian cancer
DK2609216T3 (en) * 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
KR20210131432A (ko) 2010-12-30 2021-11-02 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
WO2013096843A1 (en) 2011-12-21 2013-06-27 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
CA2864481C (en) 2012-02-23 2020-07-14 The Children's Hospital Corporation Methods for predicting anti-cancer response
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
AU2014248007B2 (en) 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
US11149316B2 (en) 2013-12-09 2021-10-19 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
ES2800673T3 (es) * 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
JP7259274B2 (ja) * 2018-11-12 2023-04-18 ソニーグループ株式会社 情報処理装置、情報処理方法、及びプログラム

Also Published As

Publication number Publication date
CN104160037B (zh) 2017-05-17
CA2860312C (en) 2022-07-12
JP6700333B2 (ja) 2020-05-27
US9388472B2 (en) 2016-07-12
DK2794907T3 (da) 2019-12-09
US20170022569A1 (en) 2017-01-26
EP2794907A4 (en) 2015-08-26
AU2020223754A1 (en) 2020-09-17
BR112014015152A2 (pt) 2017-07-04
CN107267598A (zh) 2017-10-20
AU2022228167B2 (en) 2025-04-17
ES2759533T5 (es) 2023-06-22
FI2794907T4 (fi) 2023-03-27
AU2012358244A1 (en) 2014-06-12
EP2794907B1 (en) 2019-11-13
JP2025032160A (ja) 2025-03-11
CA2860312A1 (en) 2013-06-27
EP2794907A1 (en) 2014-10-29
AU2022228167A1 (en) 2022-09-29
JP2018138031A (ja) 2018-09-06
DK2794907T4 (da) 2023-02-27
JP2022174081A (ja) 2022-11-22
NZ625468A (en) 2016-04-29
WO2013096843A1 (en) 2013-06-27
US20200190602A1 (en) 2020-06-18
JP7128853B2 (ja) 2022-08-31
JP2015506678A (ja) 2015-03-05
US20230111438A1 (en) 2023-04-13
EP4497824A2 (en) 2025-01-29
AU2018211277A1 (en) 2018-08-23
US20150018527A1 (en) 2015-01-15
CN104160037A (zh) 2014-11-19
JP7595619B2 (ja) 2024-12-06
AU2020223754B2 (en) 2022-09-29
EP3660161B1 (en) 2024-07-31
EP2794907B2 (en) 2022-11-23
US20250215509A1 (en) 2025-07-03
AU2018211277B2 (en) 2020-06-11
US10612098B2 (en) 2020-04-07
CN107267598B (zh) 2022-03-25
JP2020127416A (ja) 2020-08-27
ES2759533T3 (es) 2020-05-11
EP4497824A3 (en) 2025-04-16
EP3660161A1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
JP7595619B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
CA2802882C (en) Methods and materials for assessing loss of heterozygosity
JP6625045B2 (ja) 相同組換え欠損を評価するための方法および材料
JP2017533693A (ja) 相同組換え欠損を評価するための方法および材料
HK40120571A (en) Methods and materials for assessing loss of heterozygosity

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161031

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180412

R150 Certificate of patent or registration of utility model

Ref document number: 6325453

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250